Medicines pricing review can resume after being stalled in December 2015
Wednesday 02/01/17 – rsi.ch/news
The triennial review of the price of medicines reimbursed by health insurance companies can resume: the Federal Council approved the necessary amendments to the ordinance today, Wednesday. Thanks to this and other measures they can be saved 240 million francs.
In December 2015, the Federal Supreme Court had blocked the periodic review of the tariffs, holding that these could not be established only on the basis of the cost of preparations abroad but 
which also had to be taken into account cost-benefit ratio.
The Executive has now made it known that therapeutic efficacy And comparison with abroad they will have a equal weight to establish the final cost.
Measures have also been approved for the cost containment in the generic drug sector: in the future the price difference with the original preparation will have to be greater compared to what happens today.
The Federal Office of Public Health (FOPH) is also developing a new reference tariff system for generics, setting a maximum that compulsory health care insurance will have to reimburse.
ats/mrj
Related news: Switzerland is increasingly dependent on the pharmaceutical industry
